© The International Congress on Controversies in Stem Cell and Cellular Therapies (COSTEM).

Contact:
Tel: +44 20 3289 9552

NOVARTIS INDUSTRY SYMPOSIUM

Into the Future – New Treatment Options for Hematologic Disorders

Industry-supported Satellite Symposium

Friday, October 27
12:45-13:45
Hall A

Moderation & Introduction: Peter Bader, Germany
Ruxolitinib to counteract priming and local tissue damage in early GVHD: Robert Zeiser, Germany
Midostaurin as a new treatment option for patients with FLT3-mutated AML: Dietger Niederwieser, Germany
Insights into the treatment of leukemia patients with CAR-T cells: Peter Bader, Germany